> **来源：[研报客](https://pc.yanbaoke.cn)** # EUDA Health Holdings Limited Summary ## Core Content EUDA Health Holdings Limited (Nasdaq: EUDA) is a non-invasive wellness product and treatment services company, primarily focused on marketing advanced technologies for the prevention and longevity markets. The company operates in Malaysia, Singapore, and China, offering stem cell and T-cell immunotherapy treatments, bioenergy capsules, and EUDA-branded supplements. It also has a property management business in Singapore. ## Financial Overview - **Share Price**: $0.73 - **Market Cap**: $36.73 M - **52 Week Range**: $0.70—$4.30 - **Ave. Volume**: 523,000 - **Basic S/O**: 50.31 M - **Fully Diluted S/O**: 54.26 M - **Float**: 31.23 M - **Institutional %**: 2% - **Insider %**: 37% **Financial Data (mrq)**: - **Cash**: $0.17 M - **ST Debt**: $2.06 M - **LT Debt**: $0.00 M - **Book Value**: ($3.73) M - **EBITDA (ttm)**: ($1.85) M - **CFFO (ttm)**: ($1.99) M ## Business Developments - **Cell Therapy Expansion**: In January 2026, EUDA invested RMB 6,000,000 via a 6% convertible loan to upgrade Shenzhen Inno's cGMP facility. This facility supports iPSC expansion, stem cell preparation, immune cell therapies, and new treatments for immune health, skin health, and healthy aging. - **Partnerships in China**: EUDA established a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform with Inno and Wuhan Kaien Hospital. This includes 50,000 and 200,000 patient cell storage capacities in Southern and Central China, respectively. Additional logistics support from Guangdong Wanhai Cell Biotechnology and Shunfeng Cold Chain Logistics. - **Product Launch**: EUDA Helixe 2.0 was launched in January 2026 with smaller capsules, new packaging, and a stronger formulation for long-term wellness and anti-aging. It received New Zealand Halal certification for global Muslim market access. - **Market Expansion**: EUDA received a direct selling license in Malaysia in late October 2025 and partnered with SafeRock India Private Limited to enter the Indian market. - **Token Integration**: EUDA plans to launch a utility cryptocurrency called "QB" for payments, rewards, and access to products and services. QB Limited, based in Hong Kong, is developing the token and is the exclusive distributor for EUDA Helixé in Hong Kong and Macau. ## Revenue and EPS Projections - **Revenue (2026e)**: $27.23 M - **Diluted EPS (2026e)**: $0.08 - **P/E (2026e)**: 9.13 - **P/S (2026e)**: 1.35 **Key Changes in Model**: - Revised down Helixé sales from 105,000 to 50,000 bottles in 2026 due to delayed marketing. - Adjusted revenue estimates based on the reduced Helixé sales. - Included the impact of 12.5 million shares issued in late February 2026, which diluted EPS estimates. ## Rating and Target - **Rating**: BUY - **Target Price**: $2.75 - **Reasoning**: Based on an EV/Revenue multiple of 5 times the 2026 revenue estimate. The company's long-term potential in the longevity and wellness portfolio is considered appealing despite reduced near-term revenue. ## Key Risks - **History of Losses**: EUDA has posted losses since going public; auditors added a "going concern" clause. - **Organic Growth Uncertainty**: Model revenue growth depends on expansion of current business; no guarantees of demand. - **Unproven Operations**: Limited history with the products and services it markets. - **Reliance on Third Party Clinics**: Business depends on third-party clinic partnerships in China. - **Dependence on Shenzhen Inno**: Critical to the stem cell business; risks if Inno faces issues. - **Uncertainty Over Legacy Business**: Euda Health's digital healthcare business has been moved to discontinued operations. - **Potential Dilution**: Future share issuances for M&A and operations may dilute existing shareholders. - **Lack of Public Company Experience**: Management and board have limited experience with public companies. - **Material Weaknesses**: Internal control weaknesses in financial reporting, including account reconciliations. - **Management Turnover**: Two CEOs and three CFOs since SPAC merger; five directors have left, two forcefully. - **Illiquid Trading**: Daily trading volume is less than $1,000,000, potentially affecting large trades. ## Analyst Information - **Analyst**: William Gregozesi, CFA - **Contact**: wgregozesi@greenridgeglobal.com | +1 414 435 1110 - **Certification**: All views reflect personal opinions; no compensation tied to recommendations. ## Disclosure Highlights - Greenridge Global makes a market in EUDA's securities. - The analyst is not a director or officer of the company. - No financial interest in EUDA's securities. - Greenridge Global has not managed or co-managed a public offering in the last 12 months. - No recent compensation for investment banking services from EUDA. - No expectation of future compensation for investment banking services. - Greenridge Global does not beneficially own 1% or more of EUDA's common stock. - EUDA is a client of Greenridge Global for non-investment banking services. - No affiliate received compensation for non-investment banking services in the past 2 months. ## Conclusion EUDA Health Holdings Limited has made significant strides in expanding its cell therapy operations and launching a new product line. However, it continues to face substantial financial and operational risks, including a history of losses, unproven business models, and dependence on third parties. Despite these challenges, the company's long-term vision in the wellness and longevity markets is seen as promising, leading to a "BUY" rating with a reduced target price.